Literature DB >> 17698347

Do pathological fractures influence survival and local recurrence rate in bony sarcomas?

J A M Bramer1, A A Abudu, R J Grimer, S R Carter, R M Tillman.   

Abstract

The influence of pathological fracture on surgical management, local recurrence and survival was established in patients with high grade, localised, extremity osteosarcoma (n=484), chondrosarcoma (n=130) and Ewing's sarcoma (n=156). Limb salvage was possible in 79% of patients with a fracture compared to 84% of patients without a fracture (p=0.17). No difference in local recurrence was found between fracture and control groups. In univariate analysis, survival in the fracture group was lower than in the control group for osteosarcoma (34% versus 58%, p<0.01) and chondrosarcoma (35% versus 63%, p=0.04), but not for Ewing's sarcoma (75% versus 64%, p=0.80). In multivariate analysis, fracture remained a significant predictor of survival for osteosarcoma, but not for chondrosarcoma, where dedifferentiated subtype appeared to be decisive. Pathological fracture independently predicts worse survival in osteosarcoma, but not chondrosarcoma and Ewing's sarcoma. Limb saving surgery seems safe, if adequate resection margins are achieved.

Entities:  

Mesh:

Year:  2007        PMID: 17698347     DOI: 10.1016/j.ejca.2007.07.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  31 in total

1.  Long-term use of nerve block catheters in paediatric patients with cancer related pathologic fractures.

Authors:  L L Burgoyne; L A Pereiras; L A Bertani; R N Kaddoum; M Neel; L G Faughnan; D L Anghelescu
Journal:  Anaesth Intensive Care       Date:  2012-07       Impact factor: 1.669

Review 2.  [Biopsy of musculoskeletal tumors : Complications and avoidable errors].

Authors:  D Winkler; H Fritzsche; K-D Schaser; C Hofbauer
Journal:  Orthopade       Date:  2020-02       Impact factor: 1.087

3.  Pathologic fracture in childhood and adolescent osteosarcoma: A single-institution experience.

Authors:  Lindsay Haynes; Sue C Kaste; Kirsten K Ness; Jianrong Wu; Lucia Ortega-Laureano; Michael Bishop; Michael Neel; Bhaskar Rao; Israel Fernandez-Pineda
Journal:  Pediatr Blood Cancer       Date:  2016-11-05       Impact factor: 3.167

Review 4.  The imaging of cartilaginous bone tumours. II. Chondrosarcoma.

Authors:  H Douis; A Saifuddin
Journal:  Skeletal Radiol       Date:  2012-10-04       Impact factor: 2.199

5.  Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study.

Authors:  Kehan Song; Xiao Shi; Xin Liang; Hongli Wang; Fei Zou; Feizhou Lu; Xiaosheng Ma; Jianyuan Jiang
Journal:  Int Orthop       Date:  2018-04-21       Impact factor: 3.075

6.  Patient-oriented functional results of total femoral endoprosthetic reconstruction following oncologic resection.

Authors:  Kevin B Jones; Anthony M Griffin; Coonoor R Chandrasekar; David Biau; Antoine Babinet; Benjamin Deheshi; Robert S Bell; Robert J Grimer; Jay S Wunder; Peter C Ferguson
Journal:  J Surg Oncol       Date:  2011-06-21       Impact factor: 3.454

7.  Management and prognostic significance of pathological fractures through chondrosarcoma of the femur.

Authors:  Jose I Albergo; Czar L Gaston; Lee M Jeys; Arun Khajuria; Simon R Carter; Roger M Tillman; Adesegun T Abudu; Robert J Grimer
Journal:  Int Orthop       Date:  2015-02-25       Impact factor: 3.075

8.  The impact of pathological fractures on therapy outcome in patients with primary malignant bone tumours.

Authors:  Babak Moradi; Anita Zahlten-Hinguranage; Burkhard Lehner; Felix Zeifang
Journal:  Int Orthop       Date:  2009-12-13       Impact factor: 3.075

9.  Chemotherapy in Ewing's sarcoma.

Authors:  Sandeep Jain; Gauri Kapoor
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

10.  Telangiectatic osteosarcoma: a review of 87 cases.

Authors:  Andrea Angelini; Andreas F Mavrogenis; Giulia Trovarelli; Stefano Ferrari; Piero Picci; Pietro Ruggieri
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-28       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.